Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial

Stanley C. Jordan, Dolly Tyan, Don Stablein, Matthew McIntosh, Steve Rose, Ashley Vo, Mieko Toyoda, Connie Davis, Ron Shapiro, Deborah Adey, Dawn Milliner, Ralph Graff, Robert Steiner, Gaetano Ciancio, Shobah Sahney, Jimmy Light

Research output: Contribution to journalArticle

315 Citations (Scopus)

Abstract

Reported are the reduction of anti-HLA antibody levels and improvement of transplant rates by intravenous immunoglobulin (IVIG) in a randomized, double-blind, placebo-controlled clinical trial. Between 1997 and 2000, a total of 101 adult patients with ESRD who were highly sensitized to HLA antigens (panel reactive antibody [PRA] ≥50% monthly for 3 mo) enrolled onto an NIH-sponsored trial (IG02). Patients received IVIG or placebo. Subjects received IVIG 2 g/kg monthly for 4 mo or an equivalent volume of placebo with additional infusions at 12 and 24 mo after entry if not transplanted. If transplanted, additional infusions were given monthly for 4 mo. Baseline PRA levels were similar in both groups. However, IVIG significantly reduced PRA levels in study subjects compared with placebo. Sixteen IVIG patients (35%) and eight placebo patients (17%) were transplanted. Rejection episodes occurred in 9 of 17 IVIG and 1 of 10 placebo subjects. Seven graft failures occurred (four IVIG, three placebo) among adherent patients with similar 2-yr graft survival rates (80% IVIG, 75% placebo). With a median follow-up of 2 yr after transplant, the viable transplants functioned normally with a mean ± SEM serum creatinine of 1.68 ± 0.28 for IVIG versus 1.28 ± 0.13 mg/dl for placebo. Adverse events rates were similar in both groups. We conclude that IVIG is better than placebo in reducing anti-HLA antibody levels and improving transplantation rates in highly sensitized patients with ESRD. Transplant rates for highly sensitized patients with ESRD awaiting kidney transplants are improved with IVIG therapy.

Original languageEnglish
Pages (from-to)3256-3262
Number of pages7
JournalJournal of the American Society of Nephrology
Volume15
Issue number12
DOIs
StatePublished - Dec 1 2004

Fingerprint

Intravenous Immunoglobulins
Chronic Kidney Failure
Transplantation
Placebos
Transplants
Antibodies
Anti-Idiotypic Antibodies
Passive Immunization
Controlled Clinical Trials
Graft Survival
HLA Antigens
Creatinine
Survival Rate
Kidney

ASJC Scopus subject areas

  • Nephrology

Cite this

Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease : Report of the NIH IG02 trial. / Jordan, Stanley C.; Tyan, Dolly; Stablein, Don; McIntosh, Matthew; Rose, Steve; Vo, Ashley; Toyoda, Mieko; Davis, Connie; Shapiro, Ron; Adey, Deborah; Milliner, Dawn; Graff, Ralph; Steiner, Robert; Ciancio, Gaetano; Sahney, Shobah; Light, Jimmy.

In: Journal of the American Society of Nephrology, Vol. 15, No. 12, 01.12.2004, p. 3256-3262.

Research output: Contribution to journalArticle

Jordan, Stanley C. ; Tyan, Dolly ; Stablein, Don ; McIntosh, Matthew ; Rose, Steve ; Vo, Ashley ; Toyoda, Mieko ; Davis, Connie ; Shapiro, Ron ; Adey, Deborah ; Milliner, Dawn ; Graff, Ralph ; Steiner, Robert ; Ciancio, Gaetano ; Sahney, Shobah ; Light, Jimmy. / Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease : Report of the NIH IG02 trial. In: Journal of the American Society of Nephrology. 2004 ; Vol. 15, No. 12. pp. 3256-3262.
@article{aec158036a174dca8aa609ba3ac7885a,
title = "Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: Report of the NIH IG02 trial",
abstract = "Reported are the reduction of anti-HLA antibody levels and improvement of transplant rates by intravenous immunoglobulin (IVIG) in a randomized, double-blind, placebo-controlled clinical trial. Between 1997 and 2000, a total of 101 adult patients with ESRD who were highly sensitized to HLA antigens (panel reactive antibody [PRA] ≥50{\%} monthly for 3 mo) enrolled onto an NIH-sponsored trial (IG02). Patients received IVIG or placebo. Subjects received IVIG 2 g/kg monthly for 4 mo or an equivalent volume of placebo with additional infusions at 12 and 24 mo after entry if not transplanted. If transplanted, additional infusions were given monthly for 4 mo. Baseline PRA levels were similar in both groups. However, IVIG significantly reduced PRA levels in study subjects compared with placebo. Sixteen IVIG patients (35{\%}) and eight placebo patients (17{\%}) were transplanted. Rejection episodes occurred in 9 of 17 IVIG and 1 of 10 placebo subjects. Seven graft failures occurred (four IVIG, three placebo) among adherent patients with similar 2-yr graft survival rates (80{\%} IVIG, 75{\%} placebo). With a median follow-up of 2 yr after transplant, the viable transplants functioned normally with a mean ± SEM serum creatinine of 1.68 ± 0.28 for IVIG versus 1.28 ± 0.13 mg/dl for placebo. Adverse events rates were similar in both groups. We conclude that IVIG is better than placebo in reducing anti-HLA antibody levels and improving transplantation rates in highly sensitized patients with ESRD. Transplant rates for highly sensitized patients with ESRD awaiting kidney transplants are improved with IVIG therapy.",
author = "Jordan, {Stanley C.} and Dolly Tyan and Don Stablein and Matthew McIntosh and Steve Rose and Ashley Vo and Mieko Toyoda and Connie Davis and Ron Shapiro and Deborah Adey and Dawn Milliner and Ralph Graff and Robert Steiner and Gaetano Ciancio and Shobah Sahney and Jimmy Light",
year = "2004",
month = "12",
day = "1",
doi = "10.1097/01.ASN.0000145878.92906.9F",
language = "English",
volume = "15",
pages = "3256--3262",
journal = "Journal of the American Society of Nephrology",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "12",

}

TY - JOUR

T1 - Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease

T2 - Report of the NIH IG02 trial

AU - Jordan, Stanley C.

AU - Tyan, Dolly

AU - Stablein, Don

AU - McIntosh, Matthew

AU - Rose, Steve

AU - Vo, Ashley

AU - Toyoda, Mieko

AU - Davis, Connie

AU - Shapiro, Ron

AU - Adey, Deborah

AU - Milliner, Dawn

AU - Graff, Ralph

AU - Steiner, Robert

AU - Ciancio, Gaetano

AU - Sahney, Shobah

AU - Light, Jimmy

PY - 2004/12/1

Y1 - 2004/12/1

N2 - Reported are the reduction of anti-HLA antibody levels and improvement of transplant rates by intravenous immunoglobulin (IVIG) in a randomized, double-blind, placebo-controlled clinical trial. Between 1997 and 2000, a total of 101 adult patients with ESRD who were highly sensitized to HLA antigens (panel reactive antibody [PRA] ≥50% monthly for 3 mo) enrolled onto an NIH-sponsored trial (IG02). Patients received IVIG or placebo. Subjects received IVIG 2 g/kg monthly for 4 mo or an equivalent volume of placebo with additional infusions at 12 and 24 mo after entry if not transplanted. If transplanted, additional infusions were given monthly for 4 mo. Baseline PRA levels were similar in both groups. However, IVIG significantly reduced PRA levels in study subjects compared with placebo. Sixteen IVIG patients (35%) and eight placebo patients (17%) were transplanted. Rejection episodes occurred in 9 of 17 IVIG and 1 of 10 placebo subjects. Seven graft failures occurred (four IVIG, three placebo) among adherent patients with similar 2-yr graft survival rates (80% IVIG, 75% placebo). With a median follow-up of 2 yr after transplant, the viable transplants functioned normally with a mean ± SEM serum creatinine of 1.68 ± 0.28 for IVIG versus 1.28 ± 0.13 mg/dl for placebo. Adverse events rates were similar in both groups. We conclude that IVIG is better than placebo in reducing anti-HLA antibody levels and improving transplantation rates in highly sensitized patients with ESRD. Transplant rates for highly sensitized patients with ESRD awaiting kidney transplants are improved with IVIG therapy.

AB - Reported are the reduction of anti-HLA antibody levels and improvement of transplant rates by intravenous immunoglobulin (IVIG) in a randomized, double-blind, placebo-controlled clinical trial. Between 1997 and 2000, a total of 101 adult patients with ESRD who were highly sensitized to HLA antigens (panel reactive antibody [PRA] ≥50% monthly for 3 mo) enrolled onto an NIH-sponsored trial (IG02). Patients received IVIG or placebo. Subjects received IVIG 2 g/kg monthly for 4 mo or an equivalent volume of placebo with additional infusions at 12 and 24 mo after entry if not transplanted. If transplanted, additional infusions were given monthly for 4 mo. Baseline PRA levels were similar in both groups. However, IVIG significantly reduced PRA levels in study subjects compared with placebo. Sixteen IVIG patients (35%) and eight placebo patients (17%) were transplanted. Rejection episodes occurred in 9 of 17 IVIG and 1 of 10 placebo subjects. Seven graft failures occurred (four IVIG, three placebo) among adherent patients with similar 2-yr graft survival rates (80% IVIG, 75% placebo). With a median follow-up of 2 yr after transplant, the viable transplants functioned normally with a mean ± SEM serum creatinine of 1.68 ± 0.28 for IVIG versus 1.28 ± 0.13 mg/dl for placebo. Adverse events rates were similar in both groups. We conclude that IVIG is better than placebo in reducing anti-HLA antibody levels and improving transplantation rates in highly sensitized patients with ESRD. Transplant rates for highly sensitized patients with ESRD awaiting kidney transplants are improved with IVIG therapy.

UR - http://www.scopus.com/inward/record.url?scp=9644262465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9644262465&partnerID=8YFLogxK

U2 - 10.1097/01.ASN.0000145878.92906.9F

DO - 10.1097/01.ASN.0000145878.92906.9F

M3 - Article

C2 - 15579530

AN - SCOPUS:9644262465

VL - 15

SP - 3256

EP - 3262

JO - Journal of the American Society of Nephrology

JF - Journal of the American Society of Nephrology

SN - 1046-6673

IS - 12

ER -